VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Kura Oncology Executive Compensation (FY25)

KURA · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Troy Wilson
Latest say-on-pay support
=
June 4, 2026
Free for 3 days · no card

See how Kura Oncology’s pay stands against its peers

  • Kura Oncology's company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Where Kura Oncology sits against its disclosed peer group, with custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KURASee the plan and pricing
No card. Nothing is charged, and the trial ends on its own. After the trial: $499/month, or $5,000/year, about two months free.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
205 figures on this page: 198 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Troy Wilson: $6,239,098 → $4,735,016 (24.1% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Kura Oncology's chief executive and what were they paid?
Total compensation for Troy Wilson, President and Chief Executive Officer, came to $4,735,016 in fiscal 2025. Wilson's total moved 24.1% lower from the $6,239,098 reported for fiscal 2024.
What was Kura Oncology's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 97.7% of votes cast for or against in favor at the meeting held June 4, 2026.
Which companies are in Kura Oncology's peer group?
The disclosed peer group includes Arcus Biosciences, Arvinas, Cogent Biosciences, Crinetics Pharmaceuticals and Day One Biopharmaceuticals, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Troy Wilson
President and Chief Executive Officer
◇◇—◇◇—◇◇
Stephen Dale
Chief Medical Officer
◇◇◇◇◇—◇◇
Kathleen Ford
Chief Operating Officer
◇◇◇◇◇—◇◇
Kirsten Flowers
Former Chief Commercial and Corporate Strategy Officer
Departed during or after this year
◇◇◇◇◇—◇◇
Marc Grasso
Former Chief Financial Officer and Chief Business Officer
Departed during or after this year
◇—◇◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Troy Wilson
President and Chief Executive Officer
◇——◇◇—◇◇
Kathleen Ford
Chief Operating Officer
◇——◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Troy Wilson
President and Chief Executive Officer
◇——◇◇—◇◇
Stephen Dale
Former Chief Medical Officer
Departed during or after this year
◇——◇◇—◇◇
Kathleen Ford
Chief Operating Officer
◇——◇◇—◇◇
Teresa Bair
Chief Legal Officer and Secretary
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Troy Wilson
President and Chief Executive Officer
◇——◇◇—◇◇
Brian Powl
Chief Commercial Officer
◇—◇◇◇—◇◇
Kathleen Ford
Chief Operating Officer
◇——◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Kathleen FordOPTION◇——◇—◇◇
Stephen DaleOPTION◇——◇—◇◇
Teresa BairRSU◇——◇——◇
Teresa BairOPTION◇——◇—◇◇
Troy E. WilsonOPTION◇——◇—◇◇
Fiscal 2022, 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Kathleen FordOption◇—◇February 15, 2033
Option◇—◇January 1, 2034
Option◇—◇January 1, 2035
Option◇—◇January 25, 2032
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option——◇August 8, 2029
Option——◇January 29, 2030
Option——◇January 25, 2031
Troy WilsonOption◇—◇January 25, 2032
Option◇—◇February 15, 2033
Option◇—◇January 1, 2034
Option◇—◇January 1, 2035
RSU◇◇——
PSU◇◇——
Option——◇January 22, 2027
Option——◇January 23, 2028
Option——◇January 21, 2029
Option——◇January 29, 2030
Option——◇January 25, 2031
Brian PowlOption◇—◇August 13, 2033
Option◇—◇January 1, 2034
RSU◇◇——
Option◇—◇January 1, 2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Faheem Hasnain
◇—◇———◇
Mary T. Szela
◇—◇———◇
Carol Schafer
◇—◇———◇
Thomas Malley
◇—◇———◇
Helen Collins, M.D
◇—◇———◇
Diane Parks
◇—◇———◇
Michael Vasconcelles, M.D
◇—◇———◇
Troy E. Wilson, Ph.D., J.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Arcus Biosciences RCUS
  • Arvinas ARVN
  • Cogent Biosciences COGT
  • Crinetics Pharmaceuticals CRNX
  • Day One Biopharmaceuticals DAWN
  • IDEAYA Biosciences IDYA
  • Iovance Biotherapeutics IOVA
  • iTeos Therapeutics ITOS
  • Janux Therapeutics JANX
  • Kymera Therapeutics KYMR
  • Nuvalent NUVL
  • Relay Therapeutics RLAY
  • Revolution Medicines RVMD
  • SpringWorks Therapeutics SWTX
  • Structure Therapeutics GPCR
  • Summit Therapeutics SMMT
  • Syndax Pharmaceuticals SNDX
  • Xencor XNCR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 4, 2026=◇◇◇
2024June 5, 2025=◇◇◇
2023June 5, 2024=◇◇◇
2022May 31, 2023=◇◇◇
2021June 21, 2022=◇◇◇
2020June 22, 2021=◇◇◇
2019June 24, 2020=◇◇◇
Tell me when Kura Oncology files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Kura Oncology disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Kura Oncology sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Kura Oncology's disclosed peer group is defensible, who names Kura Oncology back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
205 figures on this page: 198 cited to the filing that reported them, 7 calculated from figures it prints.
198 cited to the filing
7 calculated from the filing

Documents cited

  1. 0001193125-26-257368
    Proposal 3. Advisory Vote on Executive Compensation For Against Abstain Broker Non-Votes
  2. 0001193125-26-151335
    Non-Employee Director Compensation
  3. 0000950170-25-083046
  4. 0000950170-25-053335
  5. 0000950170-24-070584
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000950170-24-044066
    Summary Compensation Table for Fiscal
  7. 0000950170-23-026086
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0000950170-23-012096
  9. 0000950170-22-012040
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001564590-21-034591
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001564590-20-030805
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Kura Oncology executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/KURA (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Kura Oncology and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

Biopharma & Life Sciences rankings

Peers Kura Oncology discloses

The companies named in KURA's own disclosed peer group.

Terms on this page

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}